A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
Status:
Completed
Trial end date:
2021-04-19
Target enrollment:
Participant gender:
Summary
This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety,
tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple
ascending subcutaneous (SC) doses of CB4211 in healthy non obese subjects and subjects with
NAFLD.